Abstract:Objectives: The aim of this study was to determine the course of tricuspid regurgitation (TR) after transcatheter mitral valve repair (TMVR), identify predictors for severe TR after TMVR and determine the association of severe TR after TMVR with outcome.Background: TR is often present in patients with symptomatic mitral regurgitation (MR) and is associated with increased morbidity and mortality. The clinical course of TR after TMVR has not been clearly determined.
“…However, RV function as assessed by tricuspid annular plane systolic excursion (TAPSE) was similar in both groups. Disagreeing with our data, Meijerink et al described TR regression as mainly occurring in patients with RV dysfunction at baseline [19].…”
Background: Improvement in concomitant tricuspid regurgitation (TR) after mitral valve transcatheter edge-to-edge repair (M-TEER) for mitral regurgitation (MR) occurs frequently; however factors determining the post-procedural course of TR are not well understood. We investigated the parameters associated with TR improvement after M-TEER. Methods and Results: A total of 300 patients were consecutively included in this retrospective analysis. MR and TR severity as well as heart chamber metrics were assessed before the procedure and at follow-up. Device success was achieved in 97.3% of patients. TR decreased in 30.2% of patients. Patients with improved TR were more often female, had more severe TR at baseline, and their right heart dimensions at baseline trended to be smaller. Female sex (odds ratio (OR) 2.997), baseline MR-Grade (OR 3.181) and baseline TR-Grade (OR 2.653) independently predicted TR reduction. More pronounced right heart reverse remodeling was observed in patients with improved TR. TR regression independently predicted lower mortality (hazard ratio (HR) 0.333, 95% confidence interval 0.112–0.996, p = 0.049). Conclusions: A reduction in concomitant TR severity after M-TEER occurred mainly in females and in patients with high-grade TR and MR at baseline. TR regression is associated with better survival after M-TEER.
“…However, RV function as assessed by tricuspid annular plane systolic excursion (TAPSE) was similar in both groups. Disagreeing with our data, Meijerink et al described TR regression as mainly occurring in patients with RV dysfunction at baseline [19].…”
Background: Improvement in concomitant tricuspid regurgitation (TR) after mitral valve transcatheter edge-to-edge repair (M-TEER) for mitral regurgitation (MR) occurs frequently; however factors determining the post-procedural course of TR are not well understood. We investigated the parameters associated with TR improvement after M-TEER. Methods and Results: A total of 300 patients were consecutively included in this retrospective analysis. MR and TR severity as well as heart chamber metrics were assessed before the procedure and at follow-up. Device success was achieved in 97.3% of patients. TR decreased in 30.2% of patients. Patients with improved TR were more often female, had more severe TR at baseline, and their right heart dimensions at baseline trended to be smaller. Female sex (odds ratio (OR) 2.997), baseline MR-Grade (OR 3.181) and baseline TR-Grade (OR 2.653) independently predicted TR reduction. More pronounced right heart reverse remodeling was observed in patients with improved TR. TR regression independently predicted lower mortality (hazard ratio (HR) 0.333, 95% confidence interval 0.112–0.996, p = 0.049). Conclusions: A reduction in concomitant TR severity after M-TEER occurred mainly in females and in patients with high-grade TR and MR at baseline. TR regression is associated with better survival after M-TEER.
“…Right ventricular function improved in 55% of patients and deterioration of RV function was characterised by excessive mortality [23]. Tricuspid regurgitation improved in 23-35%, and persistence of TR after TMVR was associated with impaired long-term prognosis and decreased symptomatic benefit [17,31,[38][39][40].…”
BackgroundPulmonary hypertension (PH), right ventricular (RV) dysfunction, and tricuspid regurgitation (TR) are commonly present in patients with mitral regurgitation (MR) and known to impair prognosis. This systematic review and meta-analysis aimed to determine the prognostic value of PH, RV function, and TR on mortality after transcatheter mitral valve repair (TMVR).
MethodsA systematic search was performed to identify studies investigating PH, RV function, or TR in patients who underwent TMVR. Studies were included for pooled analysis if hazard ratios (HR) for all-cause mortality were given.
ResultsA total of 8,672 patients from 21 selected studies were included (PH, 11 studies; RV function, nine studies; TR, 10 studies). Mean follow-up was 2.761.6 years. The HRs and 95% CIs for all-cause mortality of PH (dichotomised: HR 1.70 95% CI 1.00-2.87; per 10 mmHg increase in systolic PAP: HR 1.17 95% CI 1.07-1.29), RV function (dichotomised: HR 1.86 95% CI 1.45-2.38; per 5 mm decrease in TAPSE: HR 1.18 95% CI 0.97-1.43) and TR (HR 1.51 95% CI 1.28-1.79) indicated a significant association.
ConclusionPrognosis after TMVR is worse in patients with significant MR when concomitant PH, RV dysfunction, or TR are present. Careful assessment of these parameters should therefore precede clinical decision-making for TMVR. The current results encourage investigation into whether (1) intervention at an earlier stage of MR reduces incidence of PH, RV dysfunction, and TR; and (2) transcatheter treatment of concomitant TR can improve clinical outcome and prognosis for these patients.
“…The composite endpoint of deaths and rehospitalizations for heart failure was significantly more frequent in the presence of 4+/3+ (67.7 vs. 88.8%; log-rank p = 0.015) [13]. Similarly, Meijerink et al [14] found differences in the prognosis of patients undergoing MitraClip procedures depending on the coexisting tricuspid regurgitation. Survival of patients with severe TR after transcatheter mitral valve repair was 58% after two years compared to 82% for those with non, mild or moderate TR.…”
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.